Sun Pharma to acquire Organon for $14.00 per share in an all-cash deal, implying an enterprise value of $11.75 billion1234
Represents a 103% premium to Organon's April 9, 2026 unaffected closing price1
Organon, a 2021 Merck spinoff, reported $6.2 billion revenue and $1.9 billion Adjusted EBITDA for 2025, with $8.6B debt and $574M cash123
Deal to position Sun Pharma as top 3 in women's health and 7th largest biosimilar player globally23
Subject to stockholder approval, antitrust clearances, and other conditions; expected to close early 2027 with outside date January 26, 2027123
Announced April 26-27, 2026; largest overseas acquisition by an Indian pharma company13
Sources:
1. https://www.stocktitan.net/sec-filings/OGN/8-k-organon-co-reports-material-event-7395c82c00ff.html
2. https://www.biospace.com/deals/sun-pharma-beams-up-organon-in-11-75b-acquisition
3. https://njbiz.com/sun-pharma-acquires-merck-spinoff-organon-11-75b/
4. https://www.fiercepharma.com/pharma/sun-pharma-strikes-biopharmas-largest-deal-26-1175b-buyout-organon